Sarepta Therapeutics (SRPT) PT Raised to $190 at Credit Suisse
Tweet Send to a Friend
Credit Suisse analyst Martin Auster raised the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $190.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
